Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 1 of 7 PageID #: 25348
`
`UNITED STATES DISTRICT COURT
`EASTERN DISTRICT OF TEXAS
`MARSHALL DIVISION
`
`ALLERGAN, INC.,
`
`Plaintiff,
`
`v.
`
`TEVA PHARMACEUTICALS USA, INC.,
`AKORN, INC., MYLAN PHARMACEUTICALS
`INC., and MYLAN INC.,
`
`Defendants.
`
`Civil Action No. 2:15-cv-1455-WCB
`
`(Consolidated) LEAD CASE
`
`JURY TRIAL DEMANDED
`
`DEFENDANTS’ NOTICE REGARDING ALLERGAN’S DOCUMENT PRODUCTION
`ACCORDING TO THE COURT’S OCTOBER 6, 2017 ORDER (DKT. NO. 503)
`
`On October 6, 2017, the Court issued an Order (Dkt. No. 503) requiring Plaintiff
`
`Allergan, Inc. (“Allergan”) to “provide the Court, by 5 p.m., Central Time, on Tuesday, October
`
`10, 2017, with copies of those documents pertinent to the terms of the assignment of the patents-
`
`in-suit to the Tribe, including any information as to payments made or to be made either by the
`
`Tribe or by Allergan in connection with the transaction.” Dkt. No. 503 at 2. The Court further
`
`ordered the parties “to file briefs by Friday, October 13, 2017, addressing the question whether
`
`the Tribe should be joined as a co-plaintiff in this action, or whether the assignment of the
`
`patents to the Tribe should be disregarded as sham.”
`
`To facilitate compliance with the Court’s Order, Defendants seek to clarify that Allergan
`
`must produce copies of the documents to both Defendants and the Court on October 10, 2017.
`
`Second, in order to allow the defendants a full opportunity fully to analyze the sham nature of the
`
`transaction, Defendants request that Allergan’s document production include at least the
`
`following categories of documents pertinent to the terms of the assignment of the patents-in-suit
`
`to the Tribe:
`
`1
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 2 of 7 PageID #: 25349
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`All agreements, including drafts thereof, underlying the assignment of the patents-in-suit,
`including any related applications or patents, from Allergan to the Tribe.
`
`All license grants, side agreements, supplemental agreements, agreements to agree,
`and/or term sheets concerning or relating to the assignment transaction between the Tribe
`and Allergan.
`
`All documents evidencing any communications, written or oral, between Allergan, or its
`attorneys, on the one hand and the Tribe, or the Tribe’s attorneys, on the other hand
`concerning or discussing the assignment of the patents-in-suit, including any related
`applications or patents.
`
`All documents evidencing any communications, written or oral, between Allergan and
`the Tribe, or the Tribe’s attorneys, concerning or discussing any license of the patents-in-
`suit, including any drafts thereof.
`
`All documents Allergan intends to provide, has agreed to provide, or has provided to the
`House Committee on Oversight and Government Reform
`(http://www.reuters.com/article/us-allergan-patents/u-s-house-committee-launches-probe-
`of-allergan-patent-deal-idUSKCN1C8262?il=0).
`
`All agreements that incorporate by reference, or refer to, Allergan license grants, side
`agreements, supplemental agreements, agreements to agree, and/or term sheets
`concerning or relating to the alleged assignment transaction between the Tribe and
`Allergan.
`
`All agreements referenced in the alleged assignment transaction between the Tribe and
`Allergan.
`
`All documents evidencing any communications, written or oral, between Allergan, or its
`attorneys, on the one hand and the Tribe, or the Tribe’s attorneys, on the other hand
`concerning or discussing inter partes review proceedings or patents, including any
`marketing material.
`
`All documents and communications, written or oral, sufficient to show any consideration
`that the Tribe gave to Allergan as a part of the assignment transaction of the patents-in-
`suit.
`
`Defendants are hopeful that Allergan’s production will be sufficient to allow for full
`
`briefing on the question of Allergan’s transaction with the Tribe. However, in the event
`
`evaluation of Allergan’s production reveals the necessity of a 30(b)(6) or limited 30(b)(1)
`
`depositions, Defendants request leave to file a letter seeking relief from the October 13 filing and
`
`allowing Defendants to conduct such depositions on an expedited basis.
`
`2
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 3 of 7 PageID #: 25350
`
`We are willing to meet with Your Honor should the Court have any questions or concerns
`
`regarding these matters.
`
`Dated: October 6, 2017
`
`Respectfully submitted,
`
`/s/ Douglas Carsten
`Douglas Carsten (dcarsten@wsgr.com)
`Wendy Devine (wdevine@wsgr.com)
`Christina Dashe (cdashe@wsgr.com)
`WILSON SONSINI GOODRICH & ROSATI
`12235 El Camino Real, Suite 200
`San Diego, CA 92130-3002
`Phone: (858) 350-2300
`Fax: (858) 350-2399
`
`Anna G. Phillips (TX Bar No. 24090329)
`WILSON SONSINI GOODRICH & ROSATI
`900 South Capital of Texas Highway
`Las Cimas IV, Fifth Floor
`Austin, TX 78746-5546
`Phone: (512) 338-5400
`Fax: (512) 338-5499
`anphillips@wsgr.com
`
`Melissa Smith
`GILLAM & SMITH LLP
`303 S. Washington Ave.
`Marshall, Texas 75670
`Tel. 903.934.8450
`Fax 903.934.9257
`melissa@gillamsmithlaw.com
`
`Counsel for Defendants Mylan
`Pharmaceuticals Inc. and Mylan Inc.
`
`3
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 4 of 7 PageID #: 25351
`
`/s/ Michael R. Dzwonczyk
`Michael R. Dzwonczyk
`Mark Boland
`Azy S. Kokabi
`Aiyda Ghahramani Cobb
`Benjamin M Cappel
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., N.W.
`Washington, DC 20037
`Phone: 202-293-7060
`mdzwonczyk@sughrue.com
`mboland@sughrue.com
`akokabi@sughrue.com
`acobb@sughrue.com
`bcappel@sughrue.com
`
`Sailesh K. Patel
`Thomas A. Rammer
`Matthew B. Mock
`SCHIFF HARDIN LLP
`233 S. Wacker Drive, Suite 7100
`Chicago, IL 60606
`Telephone: 312-258-5500
`Facsimile: 312-258-5600
`spatel@schiffhardin.com
`trammer@schiffhardin.com
`mmock@schiffhardin.com
`
`John K. Hsu
`SCHIFF HARDIN LLP
`901 K Street NW, Suite 700
`Washington, DC 20001
`Telephone: 202-778-6467
`Facsimile: 202-778-6460
`jhsu@schiffhardin.com
`
`George Chih-Lun Yu
`SCHIFF HARDIN LLP
`One Market, Spear Street Tower
`Suite 3200
`San Francisco, CA 94105
`Tel: 415-901-8700
`gyu@schiffhardin.com
`
`E. Glenn Thames, Jr.
`Texas State Bar No. 00785097
`
`/s/ J.C. Rozendaal
`J.C. Rozendaal (pro hac vice)
`Michael Joffre (pro hac vice)
`R. Wilson Powers, III (pro hac vice)
`Pauline M. Pelletier (pro hac vice)
`William H. Milliken (pro hac vice)
`Byron L. Pickard
`STERNE, KESSLER, GOLDSTEIN & FOX,
`PLLC
`1100 New York Ave. NW
`Washington, DC 20005
`Telephone: (202) 371-2600
`Facsimile: (202) 371-2540
`jcrozendaal@skgf.com
`mjoffre@skgf.com
`tpowers@skgf.com
`ppelletier@skgf.com
`wmilliken@skgf.com
`bpickard@skgf.com
`Louis B. (“Brady”) Paddock
`Texas Bar No. 00791394
`NIX, PATTERSON & ROACH, L.L.P.
`2900 St. Michael Drive, Ste. 500
`Texarkana, TX 75503
`Telephone: (903) 223-3999
`Facsimile: (903) 223-8520
`bpaddock@nixlawfirm.com
`
`Counsel for Teva Pharmaceuticals USA,
`Inc.
`
`4
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 5 of 7 PageID #: 25352
`
`glennthames@potterminton.com
`
`POTTER MINTON
`A PROFESSIONAL CORPORATION
`110 N. College Avenue, Suite 500
`Tyler, TX 75702
`Telephone: (903) 597-8311
`Facsimile: (903) 593-0846
`
`Counsel for Akorn, Inc.
`
`/s/ Charles B. Klein
`Charles B. Klein
`(DC Bar No. 450984)
`WINSTON & STRAWN, LLP
`cklein@winston.com
`1700 K. Street, NW
`Washington, DC 20006
`Telephone: (202) 282-5000
`Facsimile: (202) 282-5100
`
`Stephen R. Smerek
`(California Bar No. 208343)
`ssmerek@winston.com
`Jason C. Hamilton
`(California Bar No. 267968)
`jhamilton@winston.com
`Shilpa Coorg
`(California Bar No. 278034)
`scoorg@winston.com
`WINSTON & STRAWN, LLP
`333 South Grand Avenue, 38th Floor
`Telephone: (213) 615-1700
`Facsimile: (213) 615-1750
`
`Deron R. Dacus
`(Texas Bar No. 00790553)
`ddacus@dacusfirm.com
`Peter Kerr
`(Texas Bar No. 24076478)
`pkerr@dacusfirm.com
`THE DACUS FIRM, PC
`821 ESE Loop 323
`Suite 430
`Tyler, TX 75701
`Telephone: (903) 705-1117
`
`5
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 6 of 7 PageID #: 25353
`
`Facsimile: (903) 581-2543
`
`Counsel for InnoPharma, Inc.
`
`6
`
`

`

`Case 2:15-cv-01455-WCB Document 504 Filed 10/06/17 Page 7 of 7 PageID #: 25354
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that the foregoing document was filed electronically in
`
`compliance with Local Rule CV-5(a) on October 6, 2017.
`
`/s/ Melissa R. Smith
`Melissa R. Smith
`
`7
`
`